Annual Report

Overview

The report describes Sun Pharma's FY19 specialty expansion, including US launches of ILUMYA, YONSA and XELPROS and four specialty-product approvals. It reports a global employee base of 32,000+ and 44 manufacturing sites across 100+ markets. Its FY19 CSR program spent ₹39.36 Million across healthcare, education, sanitation, water, environment and rural development, while 17 units had achieved zero liquid discharge and clean-energy generation reached around 2.05 Million kWh.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2019
Period: 1 April 2018 – 31 March 2019
Language: English
File size
Restatement: Disclosed

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services